Hair and skin
Pyrilutamide
An experimental topical androgen-receptor antagonist with a positive 2026 sponsor trial report, an earlier negative placebo comparison and unresolved approval evidence here.
Human sponsor-reported phase 3 findings, including conflicting trial results; limited independent detail
Also known as: KX-826
Practical use
Evidence interpretation and clinical context
- Name the trial year
- The 2023 and 2026 results have different conclusions.
- Keep the sponsor attribution
- Present unpublished topline results as company-reported findings.
- Verify the product milestone
- A cosmetic listing, trial permission, application and approval are distinct states.
KX-826 phase 3 topline results — sponsor announcement, March 2026
KX-826 phase 3 topline results — stock-exchange filing, November 2023
Overview
Pyrilutamide, or KX-826, is intended to block androgen signaling in hair follicles. Its clinical-development and cosmetic-product histories need separate treatment. A marketed cosmetic and a successful clinical trial do not themselves establish an approved medicine.
Risks and limitations
The 2026 sponsor report describes no drug-related serious adverse events and similar overall adverse-event incidence to placebo. Those topline observations do not establish long-term safety or the quality of independently sold products.
How to read this
The evidence has changed over time. An earlier phase 3 trial did not significantly outperform placebo; a later trial reported a positive placebo-adjusted hair-count result. Both belong in an accurate account.
Research explained
KX-826 phase 3 topline results — sponsor announcement, March 2026
Who was studied
666 Chinese men with androgenetic alopecia in a randomized, double-blind, vehicle-controlled study lasting 24 weeks.
What was found
The sponsor reported placebo-adjusted increases of 10.65 and 9.78 non-vellus hairs per square centimeter in two active groups; both comparisons were statistically significant.
What it cannot establish
This is a company topline announcement, not an independently reviewed full clinical report. Durability and comprehensive harms require fuller data.
Read the original studyKX-826 phase 3 topline results — stock-exchange filing, November 2023
Who was studied
A separate randomized phase 3 study in Chinese adult men with androgenetic alopecia.
What was found
Hair count increased from baseline, but the comparison with placebo was not statistically significant.
What it cannot establish
The later positive announcement does not change the outcome of this earlier trial. The two studies should not be collapsed into one uniformly positive result.
Read the original studyNovel Dual Soft Drug Strategy Enables Development of Topical Androgen Receptor Antagonists with Enhanced Efficacy and Optimized Safety for Androgenetic Alopecia.
Who was studied
A medicinal-chemistry study using pyrilutamide as a comparator in a mouse hair-growth model.
What was found
A newer experimental compound achieved comparable hair-growth effects to pyrilutamide in that model.
What it cannot establish
This is animal comparator evidence, not a human safety or effectiveness trial of pyrilutamide.
Read the original studyRegulatory milestone still needs its own evidence
The March 2026 announcement described a planned Chinese marketing application. That source does not document an approval; this guide does not infer approval from cosmetic availability.
Supporting sourceWhy the earlier result matters
The 2023 filing explicitly distinguishes a significant baseline change from a nonsignificant placebo comparison. Baseline improvement alone was insufficient to establish superiority.
Supporting sourceClaims versus findings
Incorrect
A positive baseline change proves pyrilutamide beat placebo.
The 2023 trial improved from baseline without a statistically significant placebo advantage.
Check the evidenceCommon questions
Are the 2026 results peer-reviewed clinical evidence?
The clinical numbers cited here come from the sponsor’s topline report. The separate peer-reviewed study is a mouse comparator experiment.
SourceSources
KX-826 phase 3 topline results — sponsor announcement, March 2026
KX-826 phase 3 topline results — stock-exchange filing, November 2023
Sources checked 2026-10-01.
General education; not a personal treatment plan.